Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19

  1. Carolyn T. Bramante
  2. Nicholas E. Ingraham
  3. Thomas A. Murray
  4. Schelomo Marmor
  5. Shane Hovertsen
  6. Jessica Gronski
  7. Chace McNeil
  8. Ruoying Feng
  9. Gabriel Guzman
  10. Nermine Abdelwahab
  11. Samantha King
  12. Thomas Meehan
  13. Kathryn M. Pendleton
  14. Bradley Benson
  15. Deneen Vojta
  16. Christopher J. Tignanelli
2 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Importance

Type 2 diabetes (T2DM) and obesity are significant risk factors for mortality in Covid19. Metformin has sex specific immunomodulatory effects which may elucidate treatment mechanisms in COVID-19.Objective:We sought to identify whether metformin reduced mortality from Covid19 and if sex specific interactions exist.

Design

Retrospective review of de-identified claims from UnitedHealth Group’s Clinical Discovery Database. Unadjusted and multivariate models were conducted to assess risk of mortality based on metformin and tumor necrosis factor alpha (TNFα) inhibitors as home medications in individuals with T2DM and obesity, controlling for comorbidities, medications, demographics, and state. Heterogeneity of effect was assessed by sex.

Setting

The database includes all 50 states in the United States.Participants:Persons with at least 6 months of continuous coverage from UnitedHealth Group in 2019 who were hospitalized with Covid-19. Persons in the metformin group had > 90 days of metformin claims in the 12 months before hospitalization.

Results

6,256 persons were included; 52.8% female; mean age 75 years. Metformin was associated with decreased mortality in women by logistic regression, OR 0.792 (0.640, 0.979); mixed effects OR 0.780 (0.631, 0.965); Cox proportional-hazards: HR 0.785 (0.650, 0.951); and propensity matching, OR of 0.759 (0.601, 0.960). There was no significant reduction in mortality among men. TNFα inhibitors were associated with decreased mortality, by propensity matching in a limited model, OR 0.19 (0.0378, 0.983).

Conclusions

Metformin was significantly associated with reduced mortality in women with obesity or T2DM in observational analyses of claims data from individuals hospitalized with Covid-19. This sex-specific finding is consistent with metformin’s reduction of TNFα in females over males, and suggests that metformin conveys protection in Covid-19 through TNFα effects. Prospective studies are needed to understand mechanism and causality.

Key Points

Question

Metformin has many anti-inflammatory effects, including sex-specific effects on TNFα. Is metformin protective from the Sars-CoV-2 virus, and does the effect differ by sex?

Findings

Metformin was associated with reduced mortality in women who were hospitalized with Covid-19, but not in men who were hospitalized with Covid-19.

Meaning

The sex-dependent survival by metformin use points towards TNFα reduction as a key mechanism for protection from Covid-19.

Related articles

Related articles are currently not available for this article.